文献速递心律失常冠心病

冠状动脉旁路移植术后房颤抗凝治疗:一项荟萃分析

Anticoagulation for post-operative atrial fibrillation after isolated coronary artery bypass grafting: a meta-analysis.
PubMed 文献 · Eur Heart J · 2024-01-01

该荟萃分析纳入非随机研究,评估CABG术后新发POAF患者口服抗凝(OAC)的使用与结局。POAF发生率7.9%–37.6%,15.5%接受OAC;OAC与血栓栓塞风险及死亡率无显著差异,但出血风险显著增加。

要点

  • CABG术后POAF患者血栓栓塞和出血并发症发生率较低。
  • OAC使用与血栓栓塞风险和死亡率无显著差异。

核心结论

  • CABG术后POAF患者并发症发生率低,OAC使用与出血风险增加相关。

研究设计与样本

  • 系统检索非随机研究,纳入1 698 307例CABG患者,比较OAC使用与否的结局。

主要发现

  • POAF发生率范围为7.9%至37.6%,15.5%的POAF患者接受OAC。
  • 30天内血栓栓塞事件率POAF 0.3%、非POAF 0.8%,死亡率POAF 1.0%、非POAF 0.5%,出血率POAF 1.1%、非POAF 2.7%。
  • 中位4.6年随访,POAF患者每100人年血栓栓塞1.73、死亡3.39、出血2.00;非POAF分别为1.14、2.19、1.60。
  • OAC使用者与非使用者血栓栓塞风险效应量-0.11(-0.36至0.13)、死亡率效应量-0.07(-0.21至0.07),均无显著差异。
  • OAC使用与更高出血风险相关,效应量0.32(0.06–0.58)。

临床怎么用

  • CABG术后POAF患者使用OAC需权衡出血风险,血栓栓塞和死亡获益未显著。

局限性

  • 纳入研究均为非随机设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: This study aimed to evaluate clinical outcomes in patients developing post-operative atrial fibrillation (POAF) after coronary artery bypass grafting (CABG) and characterize variations in oral anticoagulation (OAC) use, benefits, and complications. METHODS: A systematic search identified studies on new-onset POAF after CABG and OAC initiation. Outcomes included risks of thromboembolic events, bleeding, and mortality. Furthermore, a meta-analysis was conducted on these outcomes, stratified by the use or non-use of OAC. RESULTS: The identified studies were all non-randomized. Among 1 698 307 CABG patients, POAF incidence ranged from 7.9% to 37.6%. Of all POAF patients, 15.5% received OAC. Within 30 days, thromboembolic events occurred at rates of 1.0% (POAF: 0.3%; non-POAF: 0.8%) with 2.0% mortality (POAF: 1.0%; non-POAF: 0.5%). Bleeding rates were 1.1% for POAF patients and 2.7% for non-POAF patients. Over a median of 4.6 years, POAF patients had 1.73 thromboembolic events, 3.39 mortality, and 2.00 bleeding events per 100 person-years; non-POAF patients had 1.14, 2.19, and 1.60, respectively. No significant differences in thromboembolic risks [effect size -0.11 (-0.36 to 0.13)] and mortality [effect size -0.07 (-0.21 to 0.07)] were observed between OAC users and non-users. However, OAC use was associated with higher bleeding risk [effect size 0.32 (0.06-0.58)]. CONCLUSIONS: In multiple timeframes following CABG, the incidence of complications in patients who develop POAF is low. The use of OAC in patients with POAF after CABG is associated with increased bleeding risk.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. van de Kar, van Brakel, Van't Veer, et al. Anticoagulation for post-operative atrial fibrillation after isolated coronary artery bypass grafting: a meta-analysis. Eur Heart J. 2024. PMID: 38809189. doi:10.1093/eurheartj/ehae267

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。